Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

HealthSource vs ShapeIn Rx

HealthSource
Graded #97

Higher grade

vs+10.800000000000004
ShapeIn Rx
Graded #325

Lower grade

The verdict

HealthSource takes it — 71.2/100 to 60.4/100.

HealthSource grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. HealthSource is a telehealth weight-management platform offering compounded semaglutide and tirzepatide (injectable and oral sublingual) dispensed through a US-based FDA 503A licensed partner pharmacy.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueShapeIn Rx +8
66
74
Dose & formulationHealthSource +26
83
57
Clinical oversightHealthSource +20
80
60
Labs & monitoringHealthSource +2
54
52
FulfillmentHealthSource +18
80
62
Contract termsHealthSource +14
55
41
HealthSource · left barShapeIn Rx · right bar

The numbers

MetricHealthSourceShapeIn Rx
WeighScore71.2/10060.4/100
GradeCC
Scorecard rank#97#325
Semaglutide$199/mo (all doses, compounded)$199/mo (compounded)
Tirzepatide$299/mo (all doses, compounded)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
HealthSource

Graded #97 · C

Strengths

  • Three GLP-1 options: compounded semaglutide injection, tirzepatide injection, and oral sublingual tirzepatide
  • 24/7 access to care team via HIPAA-compliant platform with unlimited physician messaging
  • Every program covers the cost of medication, supplies, and telehealth visits — no separate pharmacy fee
  • Subscription auto-refund if monthly reassessment is not completed
  • Available in all 50 US states including Alaska and Hawaii with 3–5 day shipping

Where it loses points

  • No physician names or clinical leadership disclosed on public pages
  • No LegitScript certification found
  • 503A partner pharmacy not named — less transparent than providers disclosing their 503B pharmacy
  • Labs not mentioned on any product page — baseline bloodwork protocol unknown
  • WooCommerce e-commerce storefront may feel more transactional than clinical
ShapeIn Rx

Graded #325 · C

Strengths

  • One of the few telehealth providers offering compounded liraglutide as a daily alternative to weekly injections
  • Semaglutide is compounded with B12, and the combination is stated plainly
  • Publishes a street address and a staffed phone line with hours
  • States openly that telemedicine is limited to jurisdictions where its providers are licensed, rather than claiming all 50
  • LegitScript certification verified against the issued seal, not just the badge

Where it loses points

  • Advertises Trusted by 150k Americans and Excellent 4.8 with 150k happy customers, and neither figure is attributable to a verifiable review profile
  • No state list is published, only a statement that coverage is limited and a note that partner pharmacies may operate in all 50 states
  • The struck-through $199 next to $149 on the homepage reads as a discount but the two prices are different medications
  • Claims No Hidden Fees and No Monthly Membership while the Terms state subscriptions automatically renew
  • No compounding pharmacy is named, only US-Certified Pharmacy

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard